Clonal Diversity Revealed By Morphoproteomic And Copy Number Profiles Of Single Prostate Cancer Cells At Diagnosis


1Bridge Institute, University of Southern California, Los Angeles, California, USA
2Department of Urology, University of California Los Angeles, California, USA
3Departments of Biomedical Sciences and Pathology, Cedars-Sinai Medical Center, Los Angeles, California, USA
4Greater Los Angeles VA Healthcare System, Los Angeles, California, USA
5Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA

Tumor heterogeneity is prevalent in treatment-naïve prostate cancer (PCa) as well as end-stage metastatic prostate cancer. This observation may contribute to the broad range of clinical presentation, treatment response, and disease progression. To characterize molecular heterogeneity associated with de novo metastatic PCa, multiplatform single cell profiling was performed using High Definition Single Cell Analysis (HD-SCA). HD-SCA enabled morphoproteomic and morphogenomic profiling of single cells from touch preparations of tissue cores (prostate and bone marrow biopsies) as well as liquid samples (peripheral blood and bone marrow aspirate). Although peripheral blood was examined, circulating tumor cells were not definitively observed. Targeted proteomics of PTTP, BMTP, and MTCs revealed cell lineage and luminal prostate epithelial differentiation associated with PCa. Hallmark PCa copy number alterations, including PTEN and ETV6 deletions and NCOA2 amplification, were observed in cells within the primary tumor and bone marrow biopsy samples. This case demonstrates that real-time molecular profiling of cells collected through prostate and bone marrow biopsies is feasible and has the potential to elucidate the origin and evolution of metastatic tumor cells. Altogether, biological and genomic data obtained through longitudinal biopsies can be used to reveal the properties of PCa and can impact clinical management.

The authors would like to acknowledge funding in whole or in part by the Prostate Cancer Foundation Challenge Award 17CHAL04 (IPG, BSK, JH, PK); Prostate Cancer Foundation-Movember Foundation 17CHAL01 USA Award (AA, PK); Prostate Cancer Foundation-Movember Foundation 16CHAL04 (KP, PK); DOD CDMRP PC130244 (BSK); Federal funds from the National Cancer Institute PO1CA098912 (BSK); National Cancer Institute, National Institutes of Health, Leidos Biomedical Research under contract number HHSN261200800001E (JH, PK); the Jean Perkins Foundation (BSK); David and Janet Polak Foundation Fellowship in Convergent Science (PM, PK); and the Vicky Joseph Research Fellow and the Vassiliadis Research Fellow (LW, PK); Schlegel Family Endowed Fellowship Fund (PK); Kalayil and Leela Chacko, MD Fellowship (PK); Competing Financial Interests are PK: Advisor to Epic Sciences, royalty recipient from Epics Sciences, shareholder at Epic Sciences; JBH: On the Clinical Advisory Boards of Epic Sciences, Inc., La Jolla, CA and CelMatix, Inc. of NY, NY.